Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy

Kunacheewa Chutima; Feng Lei; Manasanch Elisabet E.; Bashir Qaiser; Patel Krina K.; Mehta Rohtesh; Kaufman Gregory P.; Srour Samer; Saini Neeraj; Iyer Swaminathan P.; Thomas Sheeba K.; Weber Donna M.; Orlowski Robert Z.; Qazilbash Muzaffar H.; Lee Hans C.

首页> 外文期刊>British Journal of Haematology >Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy

【24h】

Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy

机译：多种骨髓瘤患者新型三联体方案的Lenalidomide Retreatment的结果进展在Lenalidomide基础维持治疗

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《British Journal of Haematology》 |2021年第3期|共4页
作者
Kunacheewa Chutima; Feng Lei; Manasanch Elisabet E.; Bashir Qaiser; Patel Krina K.; Mehta Rohtesh; Kaufman Gregory P.; Srour Samer; Saini Neeraj; Iyer Swaminathan P.; Thomas Sheeba K.; Weber Donna M.; Orlowski Robert Z.; Qazilbash Muzaffar H.; Lee Hans C.;
展开▼
作者单位

Univ Texas MD Anderson Canc Ctr Dept Lymphoma Myeloma Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Biostat Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Lymphoma Myeloma Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Stem Cell Transplantat &

Cellular Therapy Houston TX 77030;

Univ Texas MD Anderson Canc Ctr Dept Lymphoma Myeloma Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Stem Cell Transplantat &

Cellular Therapy Houston TX 77030;

Univ Texas MD Anderson Canc Ctr Dept Lymphoma Myeloma Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Stem Cell Transplantat &

Cellular Therapy Houston TX 77030;

Univ Texas MD Anderson Canc Ctr Dept Stem Cell Transplantat &

Cellular Therapy Houston TX 77030;

Univ Texas MD Anderson Canc Ctr Dept Lymphoma Myeloma Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Lymphoma Myeloma Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Lymphoma Myeloma Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Lymphoma Myeloma Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Biostat Houston TX 77030 USA;

Univ Texas MD Anderson Canc Ctr Dept Lymphoma Myeloma Houston TX 77030 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis [J] . Wen-Wen Lyu, Qing-Chun Zhao, De-Hai Song, 中华医学杂志（英文版） . 2016,第003期
2. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma [J] . ZHANG Xiao-hui, LU Dao-pei, HUANG Xiao-jun, 中华医学杂志（英文版） . 2007,第006期
3. Progress in Drug Therapy for Multiple Myeloma [J] . Shune Yang, Bing Zhao 癌症生物学与医学（英文版） . 2008,第004期
4. Lenalidomide Maintenance Does Not Negatively Impact Overall and Progression Free Survival Using Lenalidomide-Based Regimens for Multiple Myeloma in First Relapse [J] . Cherniawsky Hannah, Breckenridge Zack M., Sandhu Irwindeep, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：在第一次复发中使用基于骨髓瘤的基于半月形的基于半月形的方案，Lenalalomide维持对整体和进展的自由生存产生负面影响
5. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. [J] . Zangari M, Fink L, Zhan F, Clinical lymphoma, myeloma & leukemia . 2011,第2期

机译：硼替佐米在多发性骨髓瘤中的静脉血栓栓塞风险低，并以沙利度胺/来那度胺为基础的治疗具有潜在的保护作用：回顾3期临床试验数据和新型联合治疗方案的研究。
6. Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study [J] . Lene Kongsgaard Nielsen, Claudia Stege, Birgit Lissenberg-Witte, Haematologica . 2020,第6期

机译：移植的健康状生活质量没有资格的新诊断的多发性骨髓瘤患者，治疗亚马亚三胺或基西拉二世德的方案，直到进展：前瞻性，开放标签，多中心，随机，第3期研究
7. Effect Analysis of PDT and VAD Regimen in the Treatment of Multiple Myeloma [C] . Jun Sun, Bo Ma, Xinyu Cui, International Conference on Biomedical Engineering, Machinery and Earth Science . 2018

机译：PDT和VAD方案治疗多发性骨髓瘤的影响分析
8. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
9. Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective open-label multicenter randomized phase 3 study [O] . Lene Kongsgaard Nielsen, Claudia Stege, Birgit Lissenberg-Witte, 2020

机译：接受以沙利度胺或来那度胺为基础的方案治疗的不符合条件的新诊断为多发性骨髓瘤患者的健康相关生活质量直至进展：一项前瞻性开放标签多中心随机3期研究
10. Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide‐based maintenance therapy [O] . Chutima Kunacheewa, Lei Feng, Elisabet E. Manasanch, 2021

机译：多种骨髓瘤患者新型三重态细胞治疗患者的延期的结果，进展在番荔枝醛族基于活性族维持疗法
11. Patient Centered Outcomes Assessment of Retreatment and Endodontic Microsurgery Using CBCT Volumetric Analysis. [R] . Curtis, D. M. 2018

机译：使用CBCT容量分析评估再治疗和根管显微外科的患者为中心的结果。

Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy

著录项

引文网络

相似文献

相关主题

期刊订阅